Information Provided By: 
Fly News Breaks for October 7, 2015
ABT
Oct 7, 2015 | 05:26 EDT
Barclays analyst Matthew Taylor upgraded Abbott Laboratories to Overweight saying the 18% selloff over the past month and a half is overdone. The company's strong fundamentals should drive "near best-in-class" top-line growth relative to its large-cap MedTech peers, Taylor tells investors in a research note. He lowered his price target for shares to $52 from $55.
News For ABT From the Last 2 Days
